Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib

Leukemia Research

Volumn 31, Issue 12, 2007, Pages 1770-1772

  Breccia, M ^a   Muscaritoli, M ^a   Gentilini, F ^a   Latagliata, R ^a   Carmosino, I ^a   Fanelli, F Rossi ^a   Alimena, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GLUCOSE; IMATINIB; INSULIN; NILOTINIB;

CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DIET RESTRICTION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; BLOOD GLUCOSE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOGLYCEMIA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 35748938796     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.01.024     Document Type: Letter

References (10)

1. Boren J., Cascante M., Marin S., Comin-Anduix B., Centelles J.J., Lim S., et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 276 (2001) 37747-37753
2. Barnes K., McIntosh E., Whetton A.D., Daley G.Q., Bentley J., and Baldwin S.A. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 24 (2005) 3257-3267
3. Breccia M., Muscaritoli M., Aversa Z., Mandelli F., and Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph + chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 22 (2005) 4653-4655
4. O'Hare T., Walters D.K., Deininger M.W.N., and Druker B.J. AMN107: tightening the grip. Cancer Cell 7 (2005) 117-119
5. Golemovic M., Verstovsek S., Giles F., Cortes J., Manshouri T., Manley P.W., et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukaemia. Clin Cancer Res 11 (2005) 4941-4947
6. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
7. Weisberg E., Manley P.W., Mestan J., Cowan-Jacob S., Ray A., Griffin J.D., et al. (Nilotinib): a novel and selective inhibitor of Bcr-Abl. Br J Cancer 94 (2006) 1765-1769
8. Kantarjian H.M., Giles F., Wunderle L., Ballha K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006) 2542-2551
9. Manley P.W., Cowan-Jacob S.W., Fendrich G., and Metan J. Molecular interactions between the higly selective pan-Bcr-Abl inhibitor, AMN107, and the tyrosine kinase domain of Abl. Blood 106 (2005) [abstract 940a]
10. White D.L., Saunders V.A., Dang P., Engler J., Zannettino A.C., Cambareri A.C., et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108 (2006) 697-704